Musk believes his ketamine use is positive for investors







Photo credit © Reuters

(Rpt 1st para)

by Sheila Dang

(Reuters) – Tesla Chief Executive Elon Musk said his ketamine use benefits his investors in a video interview posted online on Monday with former CNN anchor Don Lemon.

“The result is what matters to Wall Street,” defended Elon Musk, recalling that Tesla’s capitalization was comparable to that of the rest of the automobile sector. “From an investor perspective, if I take something, I should continue to take it.”

Read alsoCounting

Elon Musk explains that ketamine, a psychotropic drug prescribed by his doctor, allows him to deal with a “negative chemical state” comparable to depression. He specifies to consume “a small amount from time to time”.

An investigation published in January by the Wall Street Journal showed that Elon Musk had used drugs, including LSD, cocaine, hallucinogenic mushrooms and ecstasy.

Several executives of companies led by Elon Musk were concerned about these revelations, fearing that the consumption of illicit substances would call into question contracts with the American government.

Ketamine is an anesthetic whose psychotropic properties are sometimes used for recreational use. The United States prohibits its possession or consumption if it is not prescribed by a doctor.

Elon Musk did not respond to a Reuters request for comment.

(Correction: Read “Tesla CEO”)

(Reporting Sheila Dang in Dallas, French version Corentin Chappron, edited by Sophie Louet)











Reuters

©2024 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.



Source link -87